|
|
|
| Progress and Prospect on Technology and Products Development of Tumor Immunotherapy |
| LU Shan, LI Su-ning, FAN Hong |
| China National Center for Biotechnology Development, Beijing 100039, China |
|
|
|
Abstract In recent years, the breaking-through progress has been made in the research of tumor immunotherapy, and the explosive growth has been obtained in the R&D of related technology and product. Great investment has been made by many Biotech Corp and pharmaceutical companies, the international competition is becoming increasingly fierce. The emerging question confronting China is how to seize the opportunities and stand out in the international competition. An overall understanding of the development situation of the field through a comprehensive analysis of the main products, technology and future research direction of the dendritic cell-based vaccine and adoptive cell transfer therapy (ACT) featured are gtiven by CAR-T and TCR-T and anti-tumor immune checkpoint inhibitors targeted to PD-1/PD-L1, and reference for R&D work through the analysis of the technical features and development trend of immunotherapy represented by the above mentioned three approaches are provided. And for the R&D situation and the existing problems in this field, suggestions such as strengthening the overall planning, focusing on basic research, emphasizing the patent protection, enhancing the scientific supervision, are put forward to provide a reference on how to make a better development of China's tumor immune therapy.
|
|
Received: 19 July 2016
Published: 25 January 2017
|
|
|
|
|
| [1] Rosenberg S A, Lotze M T, Muul L M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine, 1987, 316(15):889-897.
[2] Mellman I, Coukos G, Dranoff G.Cancer immunotherapy comes of age.Nature,2011,480(22/29):480-489.
[3] Topalian S L, Weiner G J, Pardoll D M.Cancer immunotherapy comes of age. Journal of Clinical Oncology,2011,29(36):4828-4836.
[4] DeVita V T, Jr Rosenberg S A. Rosenberg.Two hundred years of cancer research. The New England Journal of Medicine,2012,366(23):2207.
[5] 钱其军.肿瘤免疫治疗何去何从:多角度的换位思考.中国肿瘤生物治疗杂志, 2016,23(3):308-313. Qian Q J.Where do we go now for cancer immunotherapy:transpositional consideration from different angles. Chinese Journal of Cancer Biotherapy,2016,23(3):308-313.
[6] Rosenberg S A, Restifo N P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, 348(6230):62-68.
[7] Witte M D, Coccoris M, Wolkers M C. Targeting self antigens through allogeneic TCR gene transfer. Molecular Therapy, 2004, 9(3):S103.
[8] Kayser S, Bob C, Feucht J, et al. Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy. Oncolmmunology, 2015, 4(5):e1002723.
[9] Porter D L, Hwang W T, Frey N V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7(303):303ra139.
[10] Barrett D M, Grupp S A, June C H. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. The Journal of Immunology, 2015, 195(3):755-761.
[11] Sharma P 1, Allison J P. The future of immune checkpoint therapy. Science, 2015, 348(6230):56-61.
[12] Weintraub K. The cancer defense. Scientific American, 2016, 314(4):42-51.
[13] Holko P,Kawalec P. Economic evaluation of sipuleucel-T immunetherapy in castration-resistant prostate cancer. Expert Review of Anticancer Therapy,2014,14(1):63-73.
[14] 万涛, 陈国友, 范颂华, 等. 大肠癌树突状细胞治疗性疫苗的Ⅰ/Ⅱ期临床研究//中国免疫学会,中国免疫学会第五届全国代表大会暨学术会议论文摘要, 中国免疫学会第五届会员代表大会,镇江,2006, 镇江:中国免疫学会,2006:390. Wan T, Chen G Y, Fan S H, et al. Phase I/II Clinical Trial on Therapeutic Vaccine for Colorectal Carcinoma Dendritic Cells//In:Chinese Society for Immunology, Paper Abstracts of the 5th National Academic Conference of Chinese Society for Immunology, the 5th National Academic Conference of Chinese Society for Immunology, Zhenjiang, 2006, Zhenjiang:Chinese Society for Immunology, 2006:390.
[15] 姚冰清,张俊萍.基于树突状细胞的抗肿瘤策略与思考.中国癌症防治杂志.2016,8(1):55-58. Yao B Q, Zhang J P. Thinking of dendritic cell-based anticancer strategy. Chinese Journal of Oncology Prevention and Treatment, 2016, 8(1):55-58.
[16] Yao B Q,Zhang J P.Thinking of dendritic cell-based anticancer strategy.Chinese Journal of Oncology Prevention and Treatment,2016,8(1):55-58.
[17] Yang W, Bai Y B, Xiong Y. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature, 2016, 531(7596):651-655. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
